-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Click on the image for the DJSeedin agenda
During Shang Xiaoyun
Total issue 1696
Written by Cheng Long
In the field of cell therapy, universal CAR-T (UCAR-T) has shown broader therapeutic prospects, but the allogeneic rejection limits the application of UCAR-T in the field of tumors, especially solid tumors
At present, MT-026, the fastest-growing general-purpose CAR-T cell therapy of Maoxing Bio, has shown good safety and efficacy data in an investigator-initiated clinical trial (IIT), targeting the brain glia.
"Through the CRISPR/Cas9 gene editing method, the company can make the cells remain highly viable after editing, and allow them to coexist with the patient's immune cells, achieving in vivo survival far beyond 30 days, providing a prerequisite for the treatment of solid tumors
Putting applied research experience into practice
During Shang Xiaoyun
Total issue 1696